Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 75,951 Shares

Posted by George Bondi on Sep 4th, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 75,951 shares of Illumina stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $218.23, for a total value of $16,574,786.73. Following the sale, the director directly owned 889,851 shares in the company, valued at $194,192,183.73. The trade was a 7.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina Stock Performance

Shares of NASDAQ:ILMN traded down $3.44 on Friday, hitting $218.22. The company’s stock had a trading volume of 1,728,019 shares, compared to its average volume of 1,904,505. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The company has a market capitalization of $32.95 billion, a price-to-earnings ratio of 40.71, a price-to-earnings-growth ratio of 3.02 and a beta of 1.46. The stock’s 50-day moving average is $197.58 and its two-hundred day moving average is $158.61. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts forecast that Illumina, Inc. will post 5.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Elyxium Wealth LLC acquired a new stake in shares of Illumina in the fourth quarter valued at about $25,000. Fiduciary Financial Advisors bought a new stake in shares of Illumina during the second quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. acquired a new position in shares of Illumina in the 2nd quarter valued at $32,000. Quarry LP bought a new stake in Illumina in the third quarter valued at about $32,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Illumina in the fourth quarter worth about $33,000. 89.42% of the stock is currently owned by institutional investors and hedge funds.

More Illumina News

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ILMN. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a report on Monday. Leerink Partners increased their price target on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Argus lifted their target price on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a report on Thursday. Finally, TD Cowen lifted their price target on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $191.31.

Check Out Our Latest Research Report on Illumina

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.